CAMBRIDGE, Mass., Nov. 03, 2015 (GLOBE NEWSWIRE) -- Sage Therapeutics (NASDAQ:SAGE) today announced that it will participate in three upcoming investor conferences in November:
- 24th Annual Credit Suisse Healthcare Conference on Tuesday, November 10 at 3:30 p.m. MT in Scottsdale, Ariz.
- Stifel Healthcare Conference 2015 on Wednesday, November 18 at 11:45 a.m. ET in New York City.
- Goldman Sachs US Emerging/SMID Cap Growth Conference on Thursday, November 19 at 12:30 p.m. ET in New York City.
Live webcasts of the presentations can be accessed on the investor page of SAGE's website at investor.sagerx.com. Replays of the webcasts will also be archived for up to 30 days on SAGE's website following the conferences.
About Sage Therapeutics
Sage Therapeutics (NASDAQ:SAGE) is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. SAGE has a portfolio of novel product candidates targeting critical CNS receptor systems, GABA and NMDA. SAGE's lead program, SAGE-547, is in Phase 3 clinical development for super-refractory status epilepticus, a rare and severe seizure disorder. SAGE is developing its next generation modulators, including SAGE-217 and SAGE-689, with a focus on acute and chronic CNS disorders. For more information, please visit www.sagerx.com.